|1.||De Berardis, Domenico: 10 articles (01/2015 - 02/2011)|
|2.||Martinotti, Giovanni: 8 articles (01/2015 - 02/2011)|
|3.||Di Giannantonio, Massimo: 8 articles (01/2015 - 02/2011)|
|4.||Fornaro, Michele: 7 articles (01/2015 - 09/2010)|
|5.||Serroni, Nicola: 6 articles (01/2015 - 02/2011)|
|6.||Racagni, Giorgio: 6 articles (11/2013 - 10/2007)|
|7.||Kasper, Siegfried: 6 articles (08/2013 - 03/2007)|
|8.||Gabriel, Cecilia: 6 articles (07/2012 - 10/2009)|
|9.||Cardinali, Daniel P: 6 articles (06/2011 - 01/2007)|
|10.||de Bodinat, Christian: 5 articles (04/2014 - 10/2008)|
|1.||Major Depressive Disorder (Major Depressive Disorders)
04/01/2010 - "The results showed significant antidepressant efficacy of agomelatine 50 mg/d, including a positive effect on sleep compared with placebo in outpatients with moderate to severe major depressive disorder."
01/01/2013 - "Agomelatine has favourable efficacy and tolerability versus a range of SSRIs and SNRIs - including agents considered to have superior efficacy - and may deserve benefit-risk analysis as a first-line treatment of major depressive disorder."
06/01/2013 - "The efficacy of agomelatine in elderly patients with recurrent major depressive disorder: a placebo-controlled study."
01/01/2008 - "Novartis is also conducting an 8-week phase III trial (NCT00411099) comparing the safety and efficacy of agomelatine 25 and 50 mg in patients with major depressive disorder. "
02/01/2006 - "The efficacy of 25 mg/day agomelatine in treating major depressive disorder (MDD) has been demonstrated in a number of placebo-controlled studies. "
|2.||Anxiety Disorders (Anxiety Disorder)
12/01/2012 - "The purpose of the study was to perform a review of studies that investigated the efficacy of agomelatine in the treatment of anxiety disorders (ADs) and a discussion of the clinical utility of agomelatine in this clinical population. "
10/01/2008 - "A randomized, double-blind, placebo-controlled trial was designed to assess the efficacy of agomelatine in generalized anxiety disorder (GAD). "
10/01/2008 - "Efficacy of agomelatine in generalized anxiety disorder: a randomized, double-blind, placebo-controlled study."
05/01/2015 - "Pharmacological studies revealed distinct functional properties for agomelatine, which shows "biased signaling." These observations demonstrate the existence of functionally unique MT2/5-HT2C heteromers and suggest that the antidepressant agomelatine has a distinctive profile at these sites potentially involved in its therapeutic effects on major depression and generalized anxiety disorder. "
04/01/2014 - "Agomelatine was efficacious in reducing symptoms in a short-term placebo-controlled trial in generalized anxiety disorder (GAD) and in preventing relapse in a longer term placebo-controlled study. "
|3.||Depressive Disorder (Melancholia)
01/01/2014 - "Agomelatine is proven to be an antidepressant and it has relieved anxiety symptoms and improved the quality of sleep in patients with depressive disorder. "
01/01/2009 - "The efficacy of agomelatine in major depression has thus been demonstrated at doses of 25-50 mg against the full range of symptoms that make up the depressive syndrome in patients with moderate to severe major depression."
01/01/2008 - "Based on these facts, agomelatine seems to be a drug of superior efficacy with a promising future in the treatment of depressive disorders. "
01/01/2013 - "[Efficacy of agomelatine in depressive disorders with anxiety]."
01/01/2014 - "Agomelatine in the treatment of depressive disorders in clinical practice: multicenter observational CHRONOS study."
|4.||Sleep Initiation and Maintenance Disorders (Insomnia)
01/01/2014 - "Agomelatine is effective in reducing insomnia in abstinent alcohol-dependent patients."
10/01/2008 - "Data on secondary outcome measures, including clinical response, symptoms of insomnia, and improvement in associated disability, were consistent with the efficacy of agomelatine. "
06/01/2015 - "Agomelatine was the only antidepressant with a lower likelihood of inducing insomnia than placebo. "
01/01/2014 - "The current pilot investigation shows that agomelatine might offer the prospect of becoming a valuable addition to the pharmacological repertoire for the treatment of alcohol-dependence-associated insomnia."
01/01/2012 - "A young patient with FFI was started on agomelatine 25 mg to medicate nocturnal insomnia. "
|5.||Mood Disorders (Mood Disorder)
10/01/2012 - "Agomelatine, a melatonergic antidepressant with a rapid onset of action, has been shown effective in various types of mood disorders (e.g., MDD, BPD, SAD). "
04/01/2013 - "Agomelatine, a new melatonergic antidepressant, has been shown effective in various types of mood disorders. "
08/01/2013 - "Agomelatine actually represents an intriguing option in the treatment of affective disorders."
08/01/2013 - "A critical review of the literature focusing on efficacy, safety and tolerability of agomelatine in major affective disorders was performed. "
03/01/2011 - "The recent development of a new pharmacological agent acting through melatonergic receptors (agomelatine) has confirmed the close link between the pineal gland and affective disorders."
|1.||Antidepressive Agents (Antidepressants)
|3.||S 20098 (agomelatine)
|4.||Serotonin (5 Hydroxytryptamine)
|6.||MT2 Melatonin Receptor
|7.||5-HT2C Serotonin Receptor
|1.||Drug Therapy (Chemotherapy)
|2.||Surgical Instruments (Clip)
|4.||Phototherapy (Light Therapy)